Discovery and case management are underway in the NAION MDL, with deadlines being set for document exchange and expert disclosures
Ertugliflozin was licensed for clinical usage in 2017 after it was demonstrated to decrease the risk of heart failure hospitalization (HHF)
Less common, but genuinely distressing when it happens
A patient may be a candidate for GLP-1 weight loss if they have obesity, overweight with weight-related health concerns, insulin resistance, prediabetes, type 2 diabetes risk, high blood pressure, high cholesterol, fatty liver concerns, sleep apnea risk, or repeated difficulty losing and maintaining weight with lifestyle changes alone
doi:10.1002/ijc.2910620402